

Special Issue

Vaccines Against Enteric Bacterial Pathogens in Poultry

Message from the Guest Editors

As the poultry industry transitions into the "no antibiotic era," it becomes critically imperative to advance the development of vaccines able to target emerging bacterial diseases that pose a significant economic threat to the poultry industry, with necrotic enteritis caused by *C. perfringens* being a notable example. Additionally, there is a need to control foodborne bacterial pathogens that pose threats to public health, such as *Salmonella* spp., *Campylobacter* spp., *E. coli*, and *L. monocytogenes*. This Special Issue is dedicated to showcasing recent scientific and technical advancements in vaccines that are designed to combat enteric bacterial pathogens in poultry. We extend an invitation for contributions in the form of original research or review articles, focusing on innovative vaccination strategies. This includes exploring the use of recombinant technology and nanotechnology in vaccine development and delivery, as well as investigating new immunomodulators and adjuvants like Toll-like receptor ligands, cytokines, nanoparticles, probiotics, and other novel agents to enhance vaccine immunogenicity and protective efficacy against the aforementioned bacterial pathogens.

Guest Editors

Dr. Khaled Abdelaziz

Department of Animal and Veterinary Sciences, Clemson University,
Clemson, SC 29634, USA

Dr. Ahmed Ali

Poultry Diseases Department, Faculty of Veterinary Medicine, Beni-Suef
University, Beni-Suef 62511, Egypt

Deadline for manuscript submissions

closed (31 July 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/196267

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).